Liminatus Pharma, Inc. Class A Common Stock (LIMN) Total Return Calculator with Dividends Reinvested

Liminatus Pharma, Inc. Class A Common Stock

Popular:

The total return for Liminatus Pharma, Inc. Class A Common Stock (LIMN) stock is -99.61% over the past 12 months. So far it's down 83.92% this year. The 5-year total return is -97.94%, meaning $10,000 invested in LIMN stock 5 years ago would be worth $206 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in LIMN 1 year ago, it would be worth $95 today — you'd have lost $9,905.

With Dividends Reinvested$95-99.05%

Price Only (No DRIP)$95-99.05%

Period2025-06-30 → 2026-06-26

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in LIMN

1Y$39-$9,961 (-99.6%)-99.6% CAGR

3Y$206-$9,794 (-97.9%)-72.6% CAGR

5Y$206-$9,794 (-97.9%)-54.0% CAGR

10Y$206-$9,794 (-97.9%)-32.2% CAGR

15Y$206-$9,794 (-97.9%)-22.8% CAGR

20Y$206-$9,794 (-97.9%)-17.6% CAGR

30Y$206-$9,794 (-97.9%)-12.1% CAGR

Liminatus Pharma, Inc. Class A Common Stock did not pay dividends during this period. Total return = price return.

Loading LIMN total return...

As of 2026-06-28

Performance Summary

Best Year-87.82%2025

Max Drawdown-99.42%2025-06-24 → 2026-06-24

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-83.92%	—	-83.51%	—	$1,608
1Y	-99.61%	-99.61%	-99.36%	—	$39
3Y	-97.94%	-72.60%	-97.89%	—	$206
5Y	-97.94%	-54.01%	-97.89%	—	$206
10Y	-97.94%	-32.18%	-97.89%	—	$206
15Y	-97.94%	-22.81%	-97.89%	—	$206
20Y	-97.94%	-17.65%	-97.89%	—	$206
30Y	-97.94%	-12.14%	-97.89%	—	$206

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-60.53%	-60.53%	—	+0.41%	-60.9pp
2025	-87.82%	-87.82%	—	+16.64%	-104.5pp

LIMN underperformed the S&P 500 by 120.45pp over the past year (-99.61% vs +20.84%).

Loading summary...

LIMN Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
LIMNLiminatus Pharma, Inc. Class A Common Stock	$3M	-35.5%	-83.9%	-99.6%	—	-97.9%	-97.9%	-97.9%
SIGASIGA Technologies, Inc.	$281M	-16.1%	-21.5%	-23.1%	+9.4pp	+22.4%	+12.3%	+706.9%
AGENAgenus Inc.	$126M	-8.7%	-9.6%	-41.6%	—	-91.1%	-97.3%	-96.3%
IMVTImmunovant, Inc.	$8.0B	+14.8%	+47.5%	+138.9%	—	+98.5%	+247.5%	+284.1%
PRAXPraxis Precision Medicines, Inc.	$9.5B	-6.5%	+7.9%	+602.8%	—	+1824.9%	+5.4%	-25.9%
KYMRKymera Therapeutics, Inc.	$8.8B	+33.9%	+37.3%	+111.9%	—	+342.1%	+125.5%	+200.3%
ARQTArcutis Biotherapeutics, Inc.	$3.4B	+27.9%	-5.6%	+91.1%	—	+220.5%	+0.1%	+25.6%
ACADACADIA Pharmaceuticals Inc.	$4.3B	+19.1%	-10.7%	+4.2%	—	-2.1%	-6.6%	-25.7%
INVAInnoviva, Inc.	$1.7B	+3.9%	+19.0%	+14.3%	—	+87.0%	+75.6%	+129.1%
HALOHalozyme Therapeutics, Inc.	$8.9B	+9.1%	+1.2%	+32.0%	—	+104.2%	+56.2%	+743.0%
PTGXProtagonist Therapeutics, Inc.	$7.8B	+21.9%	+40.1%	+127.6%	—	+324.9%	+184.9%	+944.0%

Compare:LIMN vs SIGA LIMN vs AGEN LIMN vs IMVT LIMN vs SIGA vs AGEN

About LIMN Dividend Returns

Liminatus Pharma, Inc. Class A Common Stock (LIMN) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of LIMN over the past year?

Liminatus Pharma, Inc. Class A Common Stock (LIMN) delivered a return of -99.61% over the past year. Since LIMN does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in LIMN be worth today?

A $10,000 investment in Liminatus Pharma, Inc. Class A Common Stock one year ago would be worth $39 today, representing a loss of $9,961.

Q3Does LIMN pay dividends?

Liminatus Pharma, Inc. Class A Common Stock (LIMN) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For LIMN, the total return equals the price-only return.

Q4Did LIMN beat the S&P 500?

No, Liminatus Pharma, Inc. Class A Common Stock (LIMN) underperformed the S&P 500 by 120.45 percentage points over the past year. LIMN delivered a total return of -99.61%, compared to the S&P 500's 20.84%. This means a passive S&P 500 index fund outperformed LIMN by 120.45pp during this period.

Q5What is LIMN's worst drawdown?

Liminatus Pharma, Inc. Class A Common Stock (LIMN) experienced a maximum drawdown of -99.42% over the past year, declining from its peak on 2025-06-24 to its trough on 2026-06-24. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is LIMN's long-term total return over 10, 20, or 30 years?

Here are Liminatus Pharma, Inc. Class A Common Stock (LIMN)'s long-term returns with dividends reinvested. Over 10 years, the total return is -97.9% (-32.2% CAGR) — $10,000 would have grown to $206. Over 20 years: -97.9% total return (-17.6% CAGR) — $10,000 → $206. Over 30 years: -97.9% total return (-12.1% CAGR) — $10,000 → $206. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

How much would $100/month in LIMN be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →